Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised £25 million in new funding.  Prokarium’s lead programme has the potential to transform the treatment paradigm in bladder cancer, one of the costliest cancers to treat. The firm says this area has seen little innovation in over 30 years. Prokarium’s pipeline leverages … Continue reading £25m backing for MedTech Prokarium